The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …

Approximately half of the patients with signs and symptoms of heart failure have a left
ventricular ejection fraction that is not markedly abnormal. Despite the historically initial …

Diffuse myocardial fibrosis resulting from the excessive deposition of collagen fibres through
the entire myocardium is encountered in a number of chronic cardiac diseases. This lesion …

Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is
rising in prevalence, is associated with high morbidity and mortality and is considered to be …

Background: The human heart primarily metabolizes fatty acids, and this decreases as
alternative fuel use rises in heart failure with reduced ejection fraction (HFrEF). Patients with …

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …

The ECM (extracellular matrix) network plays a crucial role in cardiac homeostasis, not only
by providing structural support, but also by facilitating force transmission, and by transducing …

In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …